explore -WSS

explore

author：knowledge 2025-09-30 16:28:48 - browse：91

Two people stare at a keyhole in a human head in between them, as the short-haired person on the left holds a key — first opinion coverage from STAT — Adobe

In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed various drugs until one (or a combination) finally works — a painful process that can take years. As a psychiatrist and neuroscientist, I became increasingly impatient and frustrated with this ineffective way of treating patients. This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

Since I first began exploring this question more than a decade ago, mental illness has become a global epidemic. Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. There have been a few notable approvals in recent years, and a renewal of interest by Big Pharma, following a retreat from psychiatric research in the mid to late 2000s. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug. This cycle of trial-and-error drug development producing trial-and-error treatment arises from a simple source: We have not systematized a process for learning from our failures and successes.

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

For example, take depression: While the rise of selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s seemed to provide a solution, seminal studies in the 2000s exposed fundamental limitations of our treatment options. Antidepressants are widely prescribed, but their efficacy relative to placebo is modest.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Innovation in antibiotics is ailing. 'Brain drain' may kill it

WSS

ASCO: Palliative care found as helpful given virtually as in person

'Hero' Louisville officer shot in head at mass shooting discharged over 3 months later

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Timeline: Special counsel's probe into Trump's handling of classified documents

Ultragenyx gene therapy for rare liver ailment succeeds in late

focus

explore

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

leisure time

Guidelines to prevent youth baseball injuries need more muscle

Intellia reports positive results for its CRISPR

What does generative AI mean for health care? We asked experts

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Medicare details structure of new drug price negotiation program

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

The cancer drug shortage isn’t new — and neither are the solutions

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

explore

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Kaiser's Risant Health gobbled up Geisinger. Who is next?

How to increase colonoscopy rates? Looks like an AI can help

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

Interest rates are at a 22

Ionis drug prevents swelling attacks due to hereditary angioedema

leisure time

hotspot

explore

focus